Acadia's DAYBU Wins EU Nod for Rett Syndrome, First in Region
Event summary
- European Commission approved DAYBU (trofinetide) for neurobehavioral symptoms of Rett syndrome in EU, covering 27 member states plus Iceland, Liechtenstein, Norway.
- Approval based on Phase 3 LAVENDER study showing statistically significant improvements in Rett Syndrome Behaviour Questionnaire (RSBQ) and Clinical Global Impression-Improvement (CGI-I) scales.
- DAYBU is first and only treatment for Rett syndrome in EU, addressing unmet medical need in rare neurodevelopmental disorder affecting 1 in 10,000-15,000 female births worldwide.
- Acadia to begin pricing and reimbursement negotiations with national authorities to expand DAYBU access across EU.
The big picture
This approval solidifies Acadia's position in the rare disease space, particularly in neurodevelopmental disorders. The EU market represents significant growth potential given the lack of prior treatment options for Rett syndrome. Success in pricing negotiations will be critical to realizing commercial upside, as reimbursement frameworks vary widely across member states.
What we're watching
- Market Expansion
- Whether Acadia can successfully navigate pricing and reimbursement negotiations across diverse EU healthcare systems to ensure broad patient access.
- Commercial Execution
- The pace at which Acadia can establish distribution and support infrastructure in EU to support DAYBU launch.
- Competitive Positioning
- How this approval strengthens Acadia's leadership in rare neurodevelopmental disorders and potential for follow-on indications.